en
Pharmaceuticals
Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
A C D E F G I J L M N O P R S T V X Z
Sandimmune* I.V.
(cyclosporine)
Immunosuppressant
*Sandimmune is a registered trademark
Sandostatin* / Sandostatin* LAR*
(octreotide acetate injection) / (octreotide as acetate for injectable suspension)
Synthetic Octapeptide Analogue of Somatostatin
*Sandostatin and LAR are registered trademarks
Sebivo*
(telbivudine)
Antiviral Agent
Important information for healthcare professionals (2008)
*Sebivo is a registered trademark
Seebri* Breezhaler*
(glycopyrronium bromide)
Long-acting muscarinic antagonist
*Seebri and Breezhaler are registered trademarks
Simulect*
(basiliximab)
Immunosuppressant
*Simulect is a registered trademark
Slow-K*
(potassium chloride)
Potassium Supplement
*Slow-K is a registered trademark
Stalevo*
(levodopa, carbidopa and entacapone)
Anti-parkinsonian Dopaminergic Agent
*Stalevo is a registered trademark
Starlix*
(nateglinide)
Oral Antidiabetic Agent
*Starlix is a registered trademark
Synacthen* Depot
(cosyntropin zinc hydroxide)
Adrenocorticotropic Hormone
*Synacthen is a registered trademark
Research
Novartis is one of the industry’s biggest investors in research.
Gilenya* (Fingolimod)
This information is intended for Canadian healthcare professionals only
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.